IRB#9902  
Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors

IRB#11638  
ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma

IRB#11688  
LOXO-101 in Adult Patients with Solid Tumors

IRB#11804  
Lenvatinib + Keytruda in Subjects with Advanced Solid Tumors

IRB#12008  
PDR001 in Patients with Advanced Malignancies

IRB#16198  
TTI-621 in subjects with Nivolumab and/or Ipilimumab with Advanced Solid Tumors

IRB#16712  
TTI-621 in subjects with Nivolumab and/or Ipilimumab with Advanced Solid Tumors

IRB#16804  
DCC-3014 in subjects with advanced malignancies

IRB#17521  
SNDX-6352 with or without Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

IRB#19388  
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

IRB#19390  
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

IRB#20399  
Study coming soon

IRB#18111  
PDR001 + LAG525 in subjects with solid tumors

IRB#18118  
Study of BA3011 in patients with advanced solid tumors

IRB#18303  
Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

IRB#18498  
Study of BA3021 in patients with advanced solid tumors

IRB#19277  
A Phase 1b Study of ASP1948: Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors

IRB#19303  
Study of BA3011 in patients with advanced solid tumors

IRB#19388  
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

IRB#19390  
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

IRB#20399  
Study coming soon
Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

- **NTRK, ROS1, ALK gene rearrangement**
  - IRB#15206
  - Entrectinib in Patients with Advanced or Metastatic Solid Tumors
  - Fusion-NTRK (previously treated)
  - IRB# 17674
  - Loxo-195 in fusion-NTRK (previously treated) solid tumors

- **RET Mutations**
  - IRB# 16676
  - BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors
  - IRB# 18164
  - A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

- **Fusion Proteins Specific**
  - BRD Amplifications Specific
  - MYC Amplifications Specific
  - AR Amplifications Specific

- **Melanoma**
  - IRB 20920 Study 02A coming soon
  - IRB 20920 Study 02B coming soon
  - IRB 20920 Study 02C coming soon

- **No Known Mutations**
  - IRB 21194 study coming soon

- **Tumor Mutation Burden - High**
  - IRB# 18788
  - Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
  - IRB# 15206
  - Entrectinib in Patients with Advanced or Metastatic Solid Tumors

- **NTRK, ROS1, ALK gene rearrangement**
  - IRB# 17674
  - Loxo-195 in fusion-NTRK (previously treated) solid tumors

- **RET Mutations**
  - IRB# 16676
  - BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

- **Fusion Proteins Specific**
  - BRD Amplifications Specific
  - MYC Amplifications Specific
  - AR Amplifications Specific

- **No Known Mutations**
  - IRB 21194 study coming soon

http://www.ohsu.edu/research/rda/so/knight.php